

(51) International Patent Classification:
C07D 487/04 (2006.01)(21) International Application Number:
PCT/US2012/044636(22) International Filing Date:
28 June 2012 (28.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/502,592 29 June 2011 (29.06.2011) US(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9 Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 101-8535 (JP).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **SUZUKI, Masaki** [JP/JP]; 1303 Grand Kawauchi Tower, 422-1 Okinoshima, Kawauchi-cho, Tokushima, 771-0142 (JP). **KONDO, Kazumi** [JP/JP]; 55-11 Aza-Inamoto, Nakakirai, Matsushige-cho, Itano-gun, Tokushima, 771-0212 (JP). **KURIMURA, Muneaki** [JP/JP]; 13-2 5-Bancho, Sako, Tokushima-shi, Tokushima, 770-0025 (JP). **VALLURU, Krishna Reddy** [IN/JP]; 405 Herbmeson Kakoh, 26-1 Aza-kaya, Tainohama, Kitajima-cho, Itano-gun, Tokushima, 771-0204 (JP). **TAKAHASHI, Akira** [JP/JP]; 66-8 Aza-Kaya, Tainohama, Kitajima-cho, Itano-gun, Tokushima, 771-0204 (JP). **KURODA, Takeshi** [JP/JP]; 24-13 Aza-ebisunomoto, Ejiri, Kitajima-cho, Itano-gun, Tokushima, 771-0205 (JP). **TAKAHASHI, Haruka** [JP/JP]; 31-36 Aza-Kasagodani,Hinoki, Ooasa-cho, Naruto, Tokushima, 779-0225 (JP). **FUKUSHIMA, Tae** [JP/US]; 350 Third Street, Apt 916, Cambridge, MA 02142 (US). **MIYAMURA, Shin** [JP/JP]; C/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi Chuo-ku, Osaka (JP). **GHOSH, Indranath** [IN/US]; 7 Grant Avenue, Belmont, MA 02478 (US). **DOGRA, Abhishek** [IN/US]; 6 Summer Street, Apt 1, Somerville, MA 02143 (US). **HARRIMAN, Geraldine** [US/US]; 50 S. Arnolda Road, Charlestown, RI 02813 (US). **ELDER, Amy** [US/US]; 15 Westminster Ave., Arlington, MA 02474 (US). **SHIMIZU, Satoshi** [JP/US]; 185 Freeman St. Apt 449, Brookline, MA 02446 (US). **HODGETTS, Kevin, J.** [GB/US]; 35 Middlesex Circle, Apt 6, Waltham, MA 02452 (US). **NEWCOM, Jason, S.** [US/US]; 81 Myrtle, Norfolk, MA 02056 (US).(74) Agent: **MCCARTY, Catherine, M.**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE



(57) Abstract: Methods of treating disorders using compounds (I) that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I).



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*